

# Release of Superoxide and Change in Morphology by Neutrophils in Response to Phorbol Esters: Antagonism by Inhibitors of Calcium-binding Proteins

JOHN M. ROBINSON,\* JOHN A. BADWEY,† MANFRED L. KARNOVSKY,† and MORRIS J. KARNOVSKY\*

\*Departments of Pathology and †Biological Chemistry, Harvard Medical School, Boston, Massachusetts 02115

**ABSTRACT** The ability of phorbol derivatives to function as stimulating agents for superoxide ( $O_2^-$ ) release by guinea pig neutrophils has been evaluated and compared to the known ability of each compound to activate protein kinase C. Those that activate the kinase also stimulate  $O_2^-$  release, while those that are inactive with respect to the kinase have no effect on  $O_2^-$  release. The same correlation was observed with respect to the ability of phorbol esters to induce morphological changes in neutrophils, i.e., vesiculation and reduction in granule content. Certain phenothiazines and naphthalene sulfonamides that are known antagonists of calcium-binding proteins blocked both phorbol ester-induced  $O_2^-$  release and morphological changes in these cells.

Upon stimulation, neutrophils undergo a dramatic series of biochemical and morphological changes. They display enhanced oxygen consumption that is used in the production of superoxide ( $O_2^-$ )<sup>1</sup> (for reviews see references 3 and 4). Comitant with this increase in oxidative metabolism is the release of enzymes and other proteins from intracellular granules through exocytotic processes and alterations in cellular morphology (e.g., 7, 16, 23).

A number of soluble and particulate agents stimulate neutrophils to varying degrees. Particulate stimuli (e.g., opsonized zymosan particles) induce production of  $O_2^-$  and morphological alterations after binding and internalization (e.g., 14). Soluble or 'quasi'-soluble stimuli include substances that exert their effects either by partitioning into and disordering membranes (e.g., digitonin, cis-unsaturated fatty acids) (e.g. 7, 11) or by binding to specific receptors in these cells, (e.g., immune complexes, chemotactic peptides) (e.g., 8, 24). The latter group includes 4- $\beta$ -phorbol 12-myristate 13-acetate (PMA) (37). The major binding site for PMA in all cells examined

thus far is the  $Ca^{2+}$ -activated, phospholipid-dependent protein kinase (protein kinase C) (9, 35, 45). High levels of activity for protein kinase C are found in neutrophils (21), and specific binding of PMA to these cells has been demonstrated (20, 28, 44). We have previously shown that suboptimal concentrations of PMA and  $Ca^{2+}$ -ionophore A23187 stimulate neutrophils synergistically (39).

To characterize further the interaction of phorbol esters with neutrophils, we have compared the ability of a spectrum of phorbol derivatives to stimulate both morphological alterations and  $O_2^-$  production in these cells. Comparative studies on the ability of phorbol esters to effect morphological changes in neutrophils are lacking. In addition, the list of phorbol esters tested as stimulating agents for  $O_2^-$  release has been expanded. Phenothiazines and naphthalene sulfonamides inhibit both responses. The inhibition of  $O_2^-$  release by the drugs is reversible, in contrast to an earlier study (12). This is the first report, to our knowledge, that antagonists of  $Ca^{2+}$ -binding proteins block morphological changes in neutrophils.

## MATERIALS AND METHODS

**Reagents:** Trifluoperazine (TFP), chlorpromazine (CPZ), promethazine (PMZ), ferricytochrome *c* (type VI), xanthine oxidase, Triton X-100, and all of the phorbol derivatives of Table I were purchased from Sigma Chemical Co., St. Louis, MO. Trifluoperazine sulfoxide (TFP-SO) and chlorpromazine

<sup>1</sup> *Abbreviations used in this paper:* CPZ, chlorpromazine; CPZ-SO, chlorpromazine sulfoxide; Me<sub>2</sub>SO, dimethylsulfoxide;  $O_2^-$ , superoxide; PMA, 4- $\beta$ -phorbol 12-myristate 13-acetate; PMZ, promethazine; TFP, trifluoperazine; TFP-SO, trifluoperazine sulfoxide; W<sub>5</sub>, *N*-(6-aminohexyl)-1-naphthalene sulfonamide; W<sub>7</sub>, *N*-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide.

sulfoxide (CPZ-SO) were gifts from Smith Kline & French Laboratories, Philadelphia, PA. *N*-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (*W*<sub>1</sub>) and *N*-(6-aminohexyl)-1-naphthalene sulfonamide (*W*<sub>2</sub>) were obtained from Rikaken Co., Ltd., Nagoya, Japan. Calmidazolium (compound No. R24571) was obtained from Janssen Pharmaceutica, Beerse, Belgium. Glutaraldehyde was obtained from Polysciences, Inc., Warrington, PA and from Alfa Products, Danvers, MA. Osmium tetroxide was purchased from Alfa Products. Tannic acid (No. 1764) was obtained from Mallinckrodt, Inc., St. Louis, MO. Epon 812 was purchased from Balzers Union, Hudson, NH. Sodium caseinate was obtained from Fisher Scientific Co., Pittsburg, PA. All other chemicals were of the highest available grade. Distilled-deionized water was supplied by a Barnstead ultrapure filtration system (Barnstead Co., Boston, MA).

**Preparation of Cells:** Neutrophils were harvested from the peritonea of guinea pigs (600–1,000 g) (Rockland, Inc., Gilbertville, PA) 18 h after the injection of sterile sodium caseinate as previously described (17). Cell viability as measured by trypan blue exclusion was always >93%. Cell number was determined by direct microscope counting using a hemocytometer.

**O<sub>2</sub><sup>-</sup> Production:** O<sub>2</sub><sup>-</sup> release was monitored at 37°C by the continuous spectrophotometric measurement of superoxide dismutase-inhibitable reduction of ferricytochrome *c* at 550 nm (11). The standard assay mixture (1.0 ml) consisted of Dulbecco's modified Eagle's medium that was altered (138 mM NaCl, 2.7 mM KCl, 16.2 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.47 mM KH<sub>2</sub>PO<sub>4</sub>, 0.90 mM CaCl<sub>2</sub>, 0.50 mM MgCl<sub>2</sub>, 7.5 mM D-glucose, pH 7.35) (18) containing 0.075 mM ferricytochrome *c* and 10<sup>6</sup> cells/ml. The blank contained all of the components listed above plus 20 μg/ml superoxide dismutase to correct for ferricytochrome *c* reduction by agents other than O<sub>2</sub><sup>-</sup>. The extinction coefficient for reduced minus oxidized cytochrome *c* at 550 nm was 20,000 M<sup>-1</sup> cm<sup>-1</sup> (30).

**Ultrastructural Analysis:** Morphological experiments were performed at a cell concentration of 1 × 10<sup>6</sup> cells/ml in 10 ml of the altered

Dulbecco's modified Eagle's medium described above except ferricytochrome *c* was omitted. Cells were fixed 5 min after stimulation by rapidly adding 1.0 ml of 25% glutaraldehyde. In some preparations, the fixative was modified to contain tannic acid as described by Maupin and Pollard (29). Cells were postfixated in 2% OsO<sub>4</sub> in 0.1 M phosphate buffer (pH 7.3) and then embedded in Epon as a pellet. Thin sections were cut on a diamond knife and stained with uranyl acetate and lead citrate before they were examined in a Philips 200 electron microscope (Philips Electronic Instruments, Inc., Mahwah, NJ) operated at 60 kV. At least 100 cells from each preparation were examined, and all observations were confirmed on at least three different preparations of cells.

## RESULTS

### Ability of Different Phorbol Derivatives to Stimulate Release of O<sub>2</sub><sup>-</sup>

Casein-elicited guinea pig neutrophils release O<sub>2</sub><sup>-</sup> at a rate of 51.4 ± 9.9 (mean ± SD) nmol O<sub>2</sub><sup>-</sup>/min per 10<sup>7</sup> cells (*n* = 24) when stimulated with an optimal concentration (30 ng/ml) of PMA. The structural specificity of the stimulus was assessed by testing various analogues of PMA (Table I). Only β-isomers with both the 12- and 13- positions in ester linkage were active. The nature of the carboxylic acid (e.g., myristate, acetate, benzoate) in these linkages was not crucial in the range examined.




FIGURE 1 Electron micrographs of thin sections of guinea pig neutrophils in suspension. (A) Representative control cell that was incubated in medium for 8 min at 37°C before fixation. This cell is typical of elicited guinea pig neutrophils in that it has large accumulations of glycogen (G) (38) and numerous electron dense intracellular granules. Note that there are few intracellular vesicles. × 9,750. (B) Cell that was preincubated for 3 min in medium at 37°C and then another 5 min after addition of PMA before fixation. This cell is typical of PMA-treated cells in that there are numerous cytoplasmic vesicles (arrowheads). Most of the glycogen (G) appears to be retained, but there is an apparent reduction in the number of intracellular granules. × 9,700. PMA was dissolved in Me<sub>2</sub>SO such that the final concentration of solvent was 0.25% (vol/vol) in all cases. This concentration of Me<sub>2</sub>SO did not affect the morphology of control cells.

TABLE 1. Effects of Various Phorbol Derivatives in Stimulating  $O_2^-$  Release and Morphological Alterations in Neutrophils\*

Compound	$O_2^-$ release <sup>†</sup>	Degree of morphological alteration <sup>‡</sup>
	% activity	
4- $\beta$ -Phorbol 12-myristate 13-acetate	100	++++ (8)
4- $\beta$ -Phorbol 12, 13-didecanoate	55 $\pm$ 2.65 (3)	++ (3)
4- $\beta$ -Phorbol 12, 13-dibenzoate	57 $\pm$ 12.12 (3)	++ (3)
4- $\beta$ -Phorbol 12, 13-dibutyrate	40 $\pm$ 7.94 (3)	++ (3)
4- $\beta$ -Phorbol 12-monomyristate	0 $\pm$ 0 (3)	- (3)
4- $\beta$ -Phorbol 13-monomyristate	0 $\pm$ 0 (3)	- (3)
4- $\beta$ -Phorbol	0 $\pm$ 0 (3)	- (3)
4- $\alpha$ -Phorbol 12, 13-didecanoate	0 $\pm$ 0 (3)	- (3)

\* Guinea pig neutrophils were subjected to the various phorbol derivatives (30 ng/ml), and superoxide release and morphological alterations were determined as described. Phorbol derivatives were dissolved in dimethyl sulfoxide such that the final concentration of this solvent was 0.25% (vol/vol) in all cases.

<sup>†</sup> The data for  $O_2^-$  release are expressed as the mean  $\pm$  SD relative to the rate observed with PMA. The number (n) of different cell preparations used is given in parentheses.

<sup>‡</sup> The degree of morphological alteration was determined on cell preparations that were fixed 5 min after addition of the phorbol derivative under study. The qualitative scale is: +++++, greatest degree of vesiculation and granule loss; ++, intermediate level of vesiculation and granule loss; -, no difference from untreated control cells with regard to vesiculation and granule number.

### Ultrastructural Analysis of Neutrophils Treated with Phorbol Derivatives

Unstimulated neutrophils in suspension are essentially spherical with a few short projections at the cell surface. These cells contain numerous cytoplasmic granules and few vesicles (Fig. 1A). Neutrophils treated in suspension with certain phorbol derivatives exhibit a dramatic increase in intracellular vesicles and a decrease in cytoplasmic granules (Fig. 1B). The specificity of the phorbol derivatives with respect to these changes in cellular morphology paralleled the potency of these compounds to stimulate  $O_2^-$  release (Table I). All of the observations reported here are restricted to 5 min after exposure to the stimulus; at this time, the cells had responded maximally in terms of the rate of  $O_2^-$  release (e.g., see Fig. 2C). Virtually all of the cells examined in each preparation responded similarly when exposed to a given stimulus.

### Effects of Phenothiazines and Naphthalene Sulfonamides on $O_2^-$ Release

Certain phenothiazines and naphthalene sulfonamides that inhibit a variety of  $Ca^{2+}$ -dependent proteins (e.g., calmodulin [46], protein kinase C [32]) were tested for their effects on  $O_2^-$  release from neutrophils stimulated with PMA. TFP or CPZ incubated with cells 3 min before stimulation inhibited  $O_2^-$  release in a cooperative manner (Hill coefficients = 3.2 and 2.1, respectively). Half-maximal inhibition occurred at  $\sim 5 \mu M$  TFP or  $10 \mu M$  CPZ (Fig. 2, A and B). Addition of TFP to cells after stimulation also caused an abrupt cessation of  $O_2^-$  release (Fig. 2C). Other phenothiazines were tested (Table II). PMZ at  $10 \mu M$  was less inhibitory than either TFP or CPZ. TFP-SO and CPZ-SO which are not antagonists of  $Ca^{2+}$ -binding proteins were inactive. Incubation of cells with the naphthalene sulfonamide  $W_7$  for 3 min before stimulation inhibited  $O_2^-$  release in a dose-dependent fashion. Half-max-




FIGURE 2 Effects of phenothiazines on superoxide release by PMA stimulated guinea pig neutrophils. (A) Dose-response curve for inhibition of  $O_2^-$  release by TFP (●) and CPZ (○). Cells ( $1 \times 10^6$ /ml) were pretreated with these drugs for 3 min in the assay mixture before stimulation with PMA (30 ng/ml). The percent inhibition was calculated from the equation  $(V_0 - V_i/V_0) \times 100$ , where  $V_0$  is the activity without inhibitor, and  $V_i$  is the activity with inhibitor. (B) The Hill plot for the data in A (TFP, ●; CPZ, ○). This form of the Hill equation is derived elsewhere by Taketa and Pogel (43). (C) Reaction progress curves (continuous tracings) demonstrating the effects of TFP on the  $O_2^-$ -dependent reduction of ferricytochrome c by neutrophils stimulated with PMA, which was added last to initiate the reactions. Curve a shows the initial portion of the progress curve for  $10^6$  cells/ml. TFP ( $20 \mu M$ ) inhibited  $O_2^-$  release when it was added to the assay system 3 min before stimulation (curve c) or to cells already stimulated (curve b). PMA was dissolved in  $Me_2SO$  such that the final concentration of solvent was 0.25% (vol/vol) in all cases. This concentration of  $Me_2SO$  did not affect  $O_2^-$  release.

imal inhibition with  $W_7$  occurred at  $\sim 20 \mu M$ .  $W_5$  (which is known not to interfere with  $Ca^{2+}$ -binding), the unchlorinated analogue of  $W_7$ , did not affect  $O_2^-$  release (Fig. 3). The inhibitory effects of TFP, CPZ, and  $W_7$  were completely reversed by washing the cells twice in drug-free medium (Table II). The degree of inhibition with these phenothiazines and naphthalene sulfonamides was not affected by increasing the cell concentration from  $1.0 \times 10^6$  to  $2.5 \times 10^6$ /ml. Therefore, the results obtained with both cell concentrations were analyzed together in Table II. The potent calmodulin inhibitor Calmidazolium (compound No. R24571) was found to be extremely toxic to neutrophils over the concentration range in which it inhibits calmodulin (0.25–2.0  $\mu M$ ).

### Effects of Phenothiazines and Naphthalene Sulfonamides on the Ultrastructure of Stimulated Neutrophils

Addition of TFP ( $10 \mu M$ ) to neutrophils 3 min before stimulation with PMA blocks the ultrastructural changes noted above. Cells so treated appear similar to unstimulated cells in that they contain few vesicles and a normal complement of granules (Fig. 4). In contrast, similar treatment of cells with  $10 \mu M$  TFP-SO did not block the PMA-induced alterations (Fig. 4B). The naphthalene sulfonamide  $W_7$  ( $50 \mu M$ ) also inhibited the ultrastructural changes induced with PMA (Fig. 5A), whereas  $W_5$  ( $50 \mu M$ ) did not (Fig. 5B).

TABLE II. Effects of Phenothiazines and Naphthalene Sulfonamides on  $O_2^-$  Release by Neutrophils Stimulated with PMA: Ability to Reverse the Effects by Washing the Cells

Drug additions	% Activity	
	Without washing	With washing
None	100	108 ± 19.4
TFP (10 μM)	18.5 ± 6.4	139 ± 28
TFP-SO (10 μM)	102.3 ± 11.3	ND
CPZ (10 μM)	48.9 ± 5.9	125.3 ± 27.7
CPZ-SO (10 μM)	100.9 ± 1.2	ND
PMZ (10 μM)	79.3 ± 8.4	ND
W <sub>7</sub> (50 μM)	8.1 ± 5.6	115.7 ± 16.5
W <sub>5</sub> (50 μM)	101.5 ± 14.5	ND

Neutrophils were incubated in the standard assay mixture for 3 min at 37°C with the compounds listed before stimulation with PMA. For experiments on reversibility, 5 ml of cells ( $2.5 \times 10^6$  cells/ml) were suspended in Dulbecco's modified Eagle's medium and incubated with the drugs for 3 min at 37°C. The cells were then washed twice in ice-cold medium (10 ml), suspended in the assay cuvette at a concentration of  $2.5 \times 10^6$  cells/ml, and stimulated with PMA. Superoxide was measured as described in Materials and Methods. Data are expressed as the mean ± SD for three to eight different preparations of cells. 100% activity is that observed in the absence of drugs. None of the drugs utilized affected cell viability under the conditions employed or inhibited  $O_2^-$  detection in an  $O_2^-$ -generating system (i.e., xanthine oxidase plus purine). ND, not determined. Three pairs of analogues were compared, as well as PMZ, which was only moderately effective. One member of each pair serves as a control, i.e., is known not to interfere with  $Ca^{++}$ -binding proteins.

Treatment of cells with 10 μM CPZ or PMZ resulted in partially inhibiting the morphological alterations induced by PMA, while treatment with CPZ-SO was ineffective in this regard. None of these drugs appeared to affect the ultrastructure of unstimulated cells in suspension (data not shown).

In agreement with these ultrastructural observations, phe-




FIGURE 3 Effects of naphthalene sulfonamides on  $O_2^-$  release from PMA-stimulated guinea pig neutrophils. Neutrophils ( $10^6$  cells/ml) were incubated with the indicated concentrations of W<sub>7</sub> (●) or W<sub>5</sub> (○) in the standard assay mixture for 3 min at 37°C before stimulation of  $O_2^-$  release with PMA. The mean inhibition of  $O_2^-$  release ± SD effected by these compounds at 50 μM is given by the error bars ( $n = 3$ ). The dose response curves are those of a single representative experiment. Compounds W<sub>7</sub> and W<sub>5</sub> were dissolved in Me<sub>2</sub>SO such that the final concentration of this solvent in the assay was 0.25% (vol/vol) in all cases. Thus, the total concentration of Me<sub>2</sub>SO was 0.5% (drug plus PMA). This concentration of solvent did not affect  $O_2^-$  release.




FIGURE 4 Effects of TFP and TFP-SO on PMA-induced ultrastructural changes in guinea pig neutrophils. (A) Cell that was incubated in suspension for 3 min in medium containing 10 μM TFP at 37°C and then another 5 min after addition of PMA before fixation. Note that the cell has very few cytoplasmic vesicles (arrowheads). An adjacent cell has a prominent lipid droplet (LD).  $\times 10,200$ . (B) Cell that was preincubated for 3 min in medium containing 10 μM TFP-SO at 37°C and then another 5 min after addition of PMA before fixation. Note the presence of numerous cytoplasmic vesicles (arrowheads). Some vesicles contain electron dense material (arrows), which is presumed to be part of the contents of granules that have discharged into these vesicles.  $\times 10,500$ .




FIGURE 5 Effects of naphthalene sulfonamides on PMA-induced ultrastructural changes in guinea pig neutrophils. (A) Cell that was incubated in suspension for 3 min in medium containing  $50 \mu\text{M}$   $W_7$  at  $37^\circ\text{C}$  and then another 5 min after addition of PMA before fixation. Note that the cell is quite round in appearance, has numerous granules, and has few cytoplasmic vesicles (arrowheads).  $\times 10,000$ . (B) Cell that was preincubated for 3 min in medium containing  $50 \mu\text{M}$   $W_5$  at  $37^\circ\text{C}$  and then another 5 min after addition of PMA before fixation. Note the presence of numerous cytoplasmic vesicles (arrowheads) and a reduction in the number of granules.  $\times 10,400$ .

nothiazines inhibited the release of lysozyme from guinea pig neutrophils stimulated with PMA with the following order of potency: TFP>CPZ>PMZ>>TFP-SO (data not shown). The ability of TFP and  $W_7$  to inhibit release of granule enzymes from neutrophils has been noted previously (e.g., 1, 33, 41, 42, 47).

## DISCUSSION

Certain phorbol esters can intercalate into cellular membranes and directly activate protein kinase C (e.g., 9, 45). In the present study, we show that the same phorbol esters reported to activate protein kinase C stimulate release of  $\text{O}_2^-$  and changes in morphology of guinea pig neutrophils, while those that do not activate kinase C did not affect neutrophils in the ways indicated (Table I). A role for protein kinase C in neutrophil stimulation has been intimated previously on the basis of stimulation of these cells by PMA and/or diacylglycerol (e.g., 15, 19, 31). Diacylglycerol is thought to be the physiological activator of protein kinase C (26). Stimulation of neutrophils with PMA produces rapid alterations in the phosphoproteins of these cells, the identity of which remain to be determined (e.g., 2, 40, 47).

The intracellular vesicles formed upon stimulation of neutrophils with phorbol esters are of interest. These structures were first reported in human neutrophils stimulated with PMA (37) and were then shown to occur in neutrophils from

guinea pigs and mice (5) and in murine macrophages (6). Cytochemical studies on these cells have shown that these vesicles and the plasmalemma stain for hydrogen peroxide (5, 6). It was speculated that these vesicles were derived, at least in part, from the plasmalemma and may be somewhat analogous to phagosomes.

As noted above, certain phenothiazines (i.e., TFP, CPZ) and naphthalene sulfonamides (i.e.,  $W_7$ ) inhibit a variety of  $\text{Ca}^{2+}$ -binding proteins including protein kinase C (e.g. 21, 32) and calmodulin (e.g., 46). Calmodulin modulates many of the second messenger functions of  $\text{Ca}^{2+}$  by interacting with various enzymes and certain elements of the cytoskeleton (for reviews, see references 10 and 36). Both protein kinase C and calmodulin are present in neutrophils (21, 25). The inhibitory effects of phenothiazines and naphthalene sulfonamides described here exhibit properties very similar to those reported for purified calmodulin-dependent enzymes. One may point in this regard to the order of effectiveness of the phenothiazines (i.e., TFP>CPZ>PMZ>>>TFP-SO, CPZ-SO) (Table II) (34, 46) and naphthalene sulfonamides ( $W_7$ >> $W_5$ ) (Table II and Fig. 3) (22), the reversibility of the effects of these drugs (Table II) (46), and the Hill coefficient for TFP ( $n_H = 3.2$ , Fig. 2B) (46). Similar data on reversibility and cooperativity of these drugs with purified protein kinase C are not presently available. The concentrations of TFP, CPZ, and  $W_7$  required for half-maximal inhibition of  $\text{O}_2^-$  release (i.e.,  $\sim 5$ , 10, and  $20 \mu\text{M}$ , respectively) (Figs. 2A and 3) are strikingly similar to

those observed for calmodulin-dependent processes (for review, see references 42 and 46) and considerably less than those required to inhibit protein kinase C (13, 21, 27). We have recently reported similar results with these inhibitors using human neutrophils stimulated with arachidonate (15). However, caution is necessary when comparing kinetic constants obtained with purified proteins to those obtained for cellular phenomena since parameters may be affected by differences in protein or lipid concentrations (e.g., 32), assay procedures (e.g., 34), and synergistic effects between the relevant components (39). A previous study on neutrophils obtained from guinea pig peritonea reported that inhibition of  $O_2^-$  release by phenothiazines was not reversible (12). The reason for the discrepancy with our results is unknown.

Addition of purified calmodulin to membrane fragments from stimulated neutrophils enhanced the activity of the  $O_2^-$ -producing oxidase; the ability of phenothiazines to inhibit this oxidase in vitro was also reported (25). White et al. (47) have examined the inhibitory effects of TFP on PMA-induced degranulation and protein phosphorylation patterns. Interestingly, their dose response curve for inhibition of degranulation and for phosphorylation of a 50,000-mol-wt protein is essentially identical to that which we present for inhibition of  $O_2^-$  release (Fig. 2A).

Thus, the abilities of several phorbol derivatives in stimulating neutrophils to release  $O_2^-$  and undergo morphological changes has been compared, and the effectiveness of several phenothiazines and naphthalene sulfonamides in blocking these processes have been determined. Additional work will be required to elucidate the precise mechanisms by which these compounds affect neutrophil function.

We are especially appreciative of Dr. Sylvia Hoffstein from the Smith Kline & French Laboratories, Philadelphia, for providing us with trifluoperazine sulfoxide. We wish also to thank Robert Rubin for assistance with photography.

This work was supported by grants AI 17945 and AI 03260 from the United States Public Health Service, National Institutes of Health. Animals used in this study were maintained in accordance with the guidelines of the Committee on Animals of the Harvard Medical School and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW publication No. 78-23, revised 1978). A portion of this work was presented at the 1983 meeting of The American Society for Cell Biology in San Antonio, Texas and the 1984 meeting of the Society of Biological Chemistry in St. Louis, Missouri.

Received for publication 7 January 1985, and in revised form 6 March 1985.

## REFERENCES

1. Alobaidi, T., P. H. Naccache, and R. I. Sha'afi. 1981. Calmodulin antagonists modulate rabbit neutrophil degranulation, aggregation, and stimulated oxygen consumption. *Biochem. Biophys. Acta.* 675:316-321.
2. Andrews, P. C., and B. M. Babior. 1984. Phosphorylation of cytosolic proteins by resting and activated human neutrophils. *Blood.* 64:883-890.
3. Babior, B. M. 1984. The respiratory burst of phagocytes. *J. Clin. Invest.* 73:599-601.
4. Badwey, J. A., and M. L. Karnovsky. 1980. Active oxygen species and the functions of phagocytic leukocytes. *Annu. Rev. Biochem.* 49:695-726.
5. Badwey, J. A., J. T. Curmutte, J. M. Robinson, J. K. Lazdins, R. T. Briggs, M. J. Karnovsky, and M. L. Karnovsky. 1980. Comparative aspects of oxidative metabolism of neutrophils from human blood and guinea pig peritonea: magnitude of the respiratory burst, dependence upon stimulating agents, and localization of the oxidases. *J. Cell. Physiol.* 105:541-551.
6. Badwey, J. A., J. M. Robinson, J. K. Lazdins, R. T. Briggs, M. J. Karnovsky, and M. L. Karnovsky. 1983. Comparative biochemical and cytochemical studies on superoxide and peroxide in mouse macrophages. *J. Cell. Physiol.* 115:208-216.
7. Badwey, J. A., J. T. Curmutte, J. M. Robinson, C. B. Berde, M. J. Karnovsky, and M. L. Karnovsky. 1984. Effects of free fatty acids on release of superoxide and on change of shape by human neutrophils. Reversibility by albumin. *J. Biol. Chem.* 259:7870-7877.
8. Becker, E. L., M. Sigman, and J. M. Oliver. 1979. Superoxide production induced in rabbit polymorphonuclear leukocytes by synthetic chemotactic peptides and A23187. *Am. J. Pathol.* 95:81-97.
9. Castagna, M., Y. Takai, K. Kaibuchi, K. Sano, U. Kikkawa, and Y. Nishizuka. 1982. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. *J. Biol. Chem.* 257:7847-7851.
10. Cheung, W. Y. 1980. Calmodulin plays a pivotal role in cellular regulation. *Science (Wash. DC).* 207:19-27.
11. Cohen, H. J., and M. E. Chovaniec. 1978. Superoxide generation by digitonin-stimulated guinea pig granulocytes. A basis for a continuous assay monitoring superoxide production and for the study of the activation of the generating system. *J. Clin. Invest.* 61:1081-1087.
12. Cohen, H. J., M. E. Chovaniec, and S. E. Ellis. 1980. Chlorpromazine inhibition of granulocyte superoxide production. *Blood.* 56:23-29.
13. Couturier, A., S. Bazzar, and M. Castagna. 1984. Further characterization of tumor-promoter-mediated activation of protein kinase C. *Biochem. Biophys. Res. Commun.* 121:448-455.
14. Curmutte, J. T., and B. M. Babior. 1974. Biological defense mechanisms. The effect of bacteria and serum on superoxide production by granulocytes. *J. Clin. Invest.* 53:1662-1672.
15. Curmutte, J. T., J. A. Badwey, J. M. Robinson, M. J. Karnovsky, and M. L. Karnovsky. 1984. Studies on the mechanism of superoxide release from human neutrophils stimulated with arachidonate. *J. Biol. Chem.* 259:11851-11857.
16. Davis, B. H., R. J. Walter, C. B. Pearson, E. L. Becker, and J. M. Oliver. 1982. Membrane activity and topography of f-Met-Leu-Phe treated C polymorphonuclear leukocytes. Acute and sustained responses to chemotactic peptide. *Am. J. Pathol.* 108:206-216.
17. DePierre, J., and M. L. Karnovsky. 1974. Ecto-enzymes of the guinea pig polymorphonuclear leukocytes. I. Evidence for an ecto-adenosine monophosphate, adenosine triphosphate, and *p*-nitrophenyl phosphate. *J. Biol. Chem.* 249:7111-7120.
18. Dulbecco, R., and M. Vogt. 1954. Plaque formation and isolation of pure lines with poliomyelitis. *J. Exp. Med.* 99:167-199.
19. Fujita, I., K. Irita, K. Takeshige, and S. Minakami. 1984. Diacylglycerol, 1-oleoyl-2-acetyl-glycerol, stimulates superoxide generation from human neutrophils. *Biochem. Biophys. Res. Commun.* 120:318-324.
20. Goodwin, B. J., and J. B. Weinberg. 1982. Receptor-mediated modulation of human monocyte, neutrophil, lymphocyte, and platelet function by phorbol diesters. *J. Clin. Invest.* 70:699-706.
21. Helfman, D. M., B. D. Applebaum, W. R. Vogler, and J. F. Kuo. 1983. Phospholipid-sensitive  $Ca^{2+}$ -dependent protein kinase C and its substrates in human neutrophils. *Biochem. Biophys. Res. Commun.* 116:743-750.
22. Hidaka, H., Y. Sasaki, T. Tanaka, T. Endo, S. Ohno, Y. Fujii, and T. Nagata. 1981. *N*-(6-aminohexyl)-5-chloro-naphthalene sulfonamide, a calmodulin antagonist, inhibits cell proliferation. *Proc. Natl. Acad. Sci. USA.* 78:4354-4357.
23. Hoffstein, S. T., R. S. Freidman, and G. Weissmann. 1982. Degranulation, membrane addition, and shape change during chemotactic factor-induced aggregation of human neutrophils. *J. Cell Biol.* 95:234-241.
24. Johnston, R. B., and J. E. Lehmyer. 1976. Elaboration of toxic oxygen by-products by neutrophils in a model of immune complex disease. *J. Clin. Invest.* 57:836-841.
25. Jones, H. P., G. Ghal, W. F. Petrone, and J. M. McCord. 1981. Calmodulin-dependent stimulation of the NADPH oxidase of human neutrophils. *Biochem. Biophys. Acta.* 714:152-156.
26. Kishimoto, A., Y. Takai, T. Mori, U. Kikkawa, and Y. Nishizuka. 1980. Activation of calcium and phospholipid-dependent protein kinase C by diacylglycerol, its possible relation to phosphatidylinositol turnover. *J. Biol. Chem.* 255:2273-2276.
27. Kuo, J. F., R. C. Schatzman, R. S. Turner, and G. J. Mazzei. 1984. Phospholipid-sensitive  $Ca^{2+}$ -dependent protein kinase: a major protein phosphorylation system. *Mol. Cell. Endocr.* 35:65-73.
28. Lehrer, R. I., and L. Cohen. 1981. Receptor-mediated regulation of superoxide production in human neutrophils stimulated by phorbol myristate acetate. *J. Clin. Invest.* 68:1314-1320.
29. Maupin, P., and T. D. Pollard. 1983. Improved preservation and staining of HeLa cell actin filaments, clathrin-coated membranes, and other cytoplasmic structures by tannic acid-glutaraldehyde-saponin fixation. *J. Cell Biol.* 96:51-62.
30. McCord, J. M., J. D. Crapo, and I. Fridovich. 1977. Superoxide dismutase assays: a review of methodology. In *Superoxide and Superoxide Dismutase*. A. M. Michelson, J. M. McCord, and I. Fridovich, editors. Academic Press, Inc., New York. First ed. 1.
31. McPhail, L. C., C. C. Clayton, and R. Snyderman. 1984. A potential second messenger role for unsaturated fatty acids: activation of  $Ca^{2+}$ -dependent protein kinase C. *Science (Wash. DC).* 224:622-624.
32. Mori, T., Y. Taki, R. Minakuchi, B. Yu, and Y. Nishizuka. 1980. Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated phospholipid-dependent protein kinase. *J. Biol. Chem.* 255:8378-8380.
33. Naccache, P. H., T. F. P. Molski, T. Alobaidi, E. L. Becker, H. J. Showell, and R. I. Sha'afi. 1980. Calmodulin inhibitors block neutrophil degranulation at a step distal from the mobilization of calcium. *Biochem. Biophys. Res. Commun.* 97:62-68.
34. Nelson, G. A., M. L. Andrews, and M. J. Karnovsky. 1983. Control of erythrocyte shape by calmodulin. *J. Cell. Biol.* 96:730-735.
35. Nield, J. E., L. J. Kuhn, and G. R. Vandenberg. 1983. Phorbol diester receptor copurifies with protein kinase C. *Proc. Natl. Acad. Sci. USA.* 80:36-40.
36. Rasmussen, H., and D. M. Waisman. 1982. Modulation of cell function in the calcium messenger system. *Rev. Physiol. Biochem. Pharmacol.* 95:111-148.
37. Repine, J. E., J. G. White, C. C. Clawson, and B. M. Holmes. 1974. Effects of phorbol myristate acetate on the metabolism and ultrastructure of neutrophils in chronic granulomatous disease. *J. Clin. Invest.* 54:83-90.
38. Robinson, J. M., M. L. Karnovsky, and M. J. Karnovsky. 1982. Glycogen accumulation in polymorphonuclear leukocytes, and other intracellular alterations that occur during inflammation. *J. Cell Biol.* 95:933-942.
39. Robinson, J. M., J. A. Badwey, M. L. Karnovsky, and M. J. Karnovsky. 1984. Superoxide release by neutrophils: synergistic effects of a phorbol ester and a calcium ionophore. *Biochem. Biophys. Res. Commun.* 122:734-739.
40. Schneider, C., M. Zanetti, and D. Romeo. 1981. Surface-reactive stimuli selectively increase protein phosphorylation in human neutrophils. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 127:4-8.
41. Smith, R. J., J. B. Bowman, and S. S. Iden. 1981. Effects of trifluoperazine on human neutrophil function. *Immunology.* 44:677-684.

42. Smolem, J. E., H. M. Korchak, and G. Weissmann. 1981. The roles of extracellular and intracellular calcium in lysosomal enzyme release and superoxide generation by human neutrophils. *Biochem. Biophys. Acta.* 677:512-520.
43. Taketa, K., and B. M. Pogell. 1965. Allosteric inhibition of rat liver fructose 1,6-diphosphate by adenosine 5'-monophosphate. *J. Biol. Chem.* 240:651-662.
44. Tauber, A. I., D. B. Brettler, E. A. Kennington, and P. A. Blumberg. 1982. Relation of human neutrophil phorbol ester occupancy and NADPH-oxidase activity. *Blood.* 60:333-339.
45. Vandenberg, G. R., L. J. Kuhn, and J. E. Niedel. 1984. Possible mechanism of phorbol diester-induced maturation of human promyelocytic leukemia cells. Activation of protein kinase C. *J. Clin. Invest.* 73:448-457.
46. Weiss, B., W. Prozialeck, M. Cimino, M. S. Barnette, and T. L. Wallace. 1980. Pharmacological regulation of calmodulin. *Ann. NY Acad. Sci.* 356:319-345.
47. White, J. R., C.-K. Huang, J. M. Hill, P. H. Naccache, E. L. Becker, and R. I. Sha'afi. 1984. Effect of phorbol 12-myristate 13-acetate and its analogue 4 $\alpha$ -phorbol 12, 13-didecanoate on protein phosphorylation and lysosomal enzyme release in rabbit neutrophils. *J. Biol. Chem.* 259:8605-8611.